Shine-On BioMedical Co.,Ltd.
Shine-On BioMedical Co.,Ltd. research, develops, and manufactures anti-cancer related drug products. It also develops antibody anticancer drugs, such as exosome anti-cancer drugs, that includes SOB101 and SOB102; SOB201 for engineered multi-target exosomes; SOA101, a dual immune checkpoint T cell adapter antibody; and SOA201, a trispecific adapter immune cell antibody. Shine-On BioMedical Co.,Ltd… Read more
Shine-On BioMedical Co.,Ltd. (6926) - Total Liabilities
Latest total liabilities as of June 2025: NT$9.15 Million TWD
Based on the latest financial reports, Shine-On BioMedical Co.,Ltd. (6926) has total liabilities worth NT$9.15 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shine-On BioMedical Co.,Ltd. - Total Liabilities Trend (2021–2024)
This chart illustrates how Shine-On BioMedical Co.,Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shine-On BioMedical Co.,Ltd. Competitors by Total Liabilities
The table below lists competitors of Shine-On BioMedical Co.,Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Swelect Energy Systems Limited
NSE:SWELECTES
|
India | ₹8.61 Billion |
|
Scottie Resources Corp
OTCQB:SCTSF
|
USA | $2.13 Million |
|
Coreline Soft, Co., Ltd.
KQ:384470
|
Korea | ₩21.40 Billion |
|
Hsin Ba Ba Corp
TW:9906
|
Taiwan | NT$7.89 Billion |
|
Gala Precision Engineering
NSE:GALAPREC
|
India | ₹719.30 Million |
|
Boab Metals Limited
PINK:PMYLF
|
USA | $748.07K |
|
Waga Energy SA
PA:WAGA
|
France | €220.13 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Shine-On BioMedical Co.,Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 115.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shine-On BioMedical Co.,Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shine-On BioMedical Co.,Ltd. (2021–2024)
The table below shows the annual total liabilities of Shine-On BioMedical Co.,Ltd. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$42.21 Million | +81.51% |
| 2023-12-31 | NT$23.25 Million | +461.31% |
| 2022-12-31 | NT$4.14 Million | -2.63% |
| 2021-12-31 | NT$4.25 Million | -- |